AstraZeneca's weight loss pill enters phase three after nearly 12% weight loss

Pharmaceutical company "AstraZeneca" presented the full results from two "phase II" trials of its experimental oral obesity medication "elecoglipron" during the American Diabetes Association's 2026 Scientific Sessions in New Orleans. The once-daily pill led to an "average body weight reduction" of 10.5% over 26 weeks and 11.8% over 36 weeks in adults with "obesity" or "overweight." The data, published in parallel in the journal "The Lancet," showed no signs of a "plateau" in weight reduction – an argument the company cites as the basis for launching a "large-scale program" of phase III clinical trials.

The "VISTA" study: nearly 9 out of 10 achieve at least 5% reduction

The "VISTA" trial included 310 adults with "obesity" or "overweight" and at least one weight-related "comorbidity." Among participants receiving "elecoglipron" at a 75 mg dose, up to "88.8%" achieved a body mass reduction of at least 5% over 26 weeks – compared to only "0.6%" in the "placebo" group.

Beyond the effect on weight, the medication also demonstrated significant "improvement in cardiometabolic markers": a "reduction in blood pressure" and a "decrease in C-reactive protein levels" – a marker for systemic inflammation – were recorded. This positions "elecoglipron" not only as a weight reduction agent but also as a potential tool in managing cardiovascular risk in patients with metabolic syndrome.

The "SOLSTICE" study: addressing obesity and diabetes simultaneously

The parallel "SOLSTICE" trial evaluated the effect of "elecoglipron" in 406 adult patients with "type 2 diabetes." The results are equally promising: at a 75 mg dosage, the average reduction in "HbA1c" – a key indicator for long-term blood sugar control – reached "1.9%" compared to "0.2%" in the placebo group.

The company reports that "90%" of patients on the maximum dose achieved an "HbA1c below 7%," and "85%" – below 6.5%. In addition to glycemic control, the medication also provided a "body weight reduction" of 7.7% over 26 weeks in diabetic patients. Thus, "elecoglipron" emerges as a dual-target treatment – against both obesity and poorly controlled type 2 diabetes.

The path to phase III and AstraZeneca's strategic moves

"AstraZeneca" announced back in February that both trials had reached their "primary endpoints," but detailed results were reserved for presentation at the "ADA" forum. The company licensed "elecoglipron" from China's "Eccogene" in 2023 and stated its intention to begin "phase III studies" in 2026, building on current efficacy and safety data.

The company's leadership, including CEO "Pascal Soriot," emphasizes that it expects "high competitiveness" of the oral candidate compared to already available weight reduction therapies. Parallel to this, "AstraZeneca" is strengthening its portfolio in the field of "cardiometabolic diseases" after signing an $18.5 billion "licensing agreement" with "CSPC Pharmaceuticals" for "long-acting weight reduction" drugs.

Competitive market: against "Foundayo" and the tablet "Wegovy"

"Elecoglipron" aims to enter a "rapidly developing and highly competitive market." In April, the "FDA" approved the oral "GLP-1 agonist" "Foundayo" (orforglipron) from "Eli Lilly." In the key phase III "ATTAIN-1" trial, the maximum dose of "Foundayo," taken for 72 weeks, led to a "12.4%" reduction in body weight.

Almost in parallel, "Novo Nordisk" launched a tablet form of its blockbuster "Wegovy," which until that point had been administered solely as injections. This marks a new race in the oral therapy segment – with an emphasis not only on efficacy but also on patient convenience and safety profile.

Competitiveness: 11.8% drop in 36 weeks

A body mass reduction of "11.8%" with "elecoglipron" taken for "36 weeks" – an approximately "twice as short period" compared to the key "Foundayo" study – suggests "high potential" for competitiveness. Nevertheless, experts emphasize that a "direct comparison" between results from different clinical trials is incorrect because the designs, populations, and endpoints differ.

Unlike "Foundayo," it will still be "several years" before any potential regulatory approval of "elecoglipron." The upcoming phase III trials will need to confirm both the "efficacy" and the "long-term safety profile" of the drug, especially in light of the increased attention to the side effects of GLP-1 agonists.

The wider context: obesity as a new "battlefield"

As the world faces the rapidly growing incidence of "obesity" and "type 2 diabetes," new oral therapies like "elecoglipron" open the possibility for wider access to treatment – especially for patients who have difficulties with injectable forms or who need combined therapy for weight and glycemia.

The results from "VISTA" and "SOLSTICE" reinforce the impression that the battle for this market will be fought not only on the lines of "percentage of weight lost" but also regarding "safety," "comfort of administration," and "additional benefits" – such as improvement in cardiovascular markers. For "AstraZeneca," "elecoglipron" is not just a new product, but a strategic move toward establishing the company as a key player in the new wave of anti-obesity drugs.